{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:32:37Z","timestamp":1780918357413,"version":"3.54.1"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.prp.2023.154988","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T23:27:37Z","timestamp":1701300457000},"page":"154988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["EZH2 as a potential therapeutic target for gastrointestinal cancers"],"prefix":"10.1016","volume":"253","author":[{"given":"Mehrdad","family":"Hashemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh","family":"Nazdari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazaleh","family":"Gholamiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid Deldar Abad","family":"Paskeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Moghadas","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Nemati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Khodaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Abyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"behdadfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Raei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasoul","family":"Raesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Nabavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Taheriazam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliheh","family":"Entezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2023.154988_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","article-title":"The matrix in cancer","volume":"21","author":"Cox","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib2","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s11033-020-06115-w","article-title":"Programmed cell death 1 (PDCD1) gene haplotypes and susceptibility of patients to basal cell carcinoma","volume":"48","author":"Fathi","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.prp.2023.154988_bib3","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3390\/ph14121315","article-title":"The therapeutic potential of common herbal and nano-based herbal formulations against ovarian cancer: New insight into the current evidence","volume":"14","author":"Rezaei-Tazangi","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.prp.2023.154988_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2023.105705","article-title":"Curcumin and its novel formulations for the treatment of hepatocellular carcinoma: New trends and future perspectives in cancer therapy","volume":"108","author":"Meybodi","year":"2023","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.prp.2023.154988_bib5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/jcb.30471","article-title":"Mesenchymal stem cells and ovarian cancer: Is there promising news?","volume":"124","author":"Jahani","year":"2023","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.prp.2023.154988_bib6","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1007\/s11033-022-07739-w","article-title":"Umbilical cord mesenchymal stem cells and breast cancer: a good therapeutic candidate or not? A minireview","volume":"49","author":"Tavakoli","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.prp.2023.154988_bib7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: Epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/4558299","article-title":"Ameliorating Effects of Curcumin on Testicular Cancer","volume":"2023","author":"Arefnezhad","year":"2023","journal-title":"Andrologia"},{"key":"10.1016\/j.prp.2023.154988_bib9","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.3390\/ijerph17218089","article-title":"Impact of gene\u2013environment interactions on cancer development","volume":"17","author":"Mbemi","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.prp.2023.154988_bib10","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(21)00279-5","article-title":"Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study","volume":"22","author":"Rumgay","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.30864","article-title":"Risks of light and moderate alcohol use in fatty liver disease: follow\u2010up of population cohorts","volume":"71","author":"\u00c5berg","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.prp.2023.154988_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","article-title":"Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load","volume":"1","author":"Peleg","year":"2019","journal-title":"JHEP Rep."},{"key":"10.1016\/j.prp.2023.154988_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2021.108365","article-title":"Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer","volume":"787","author":"Caliri","year":"2021","journal-title":"Mutat. Res. \/Rev. Mutat. Res."},{"key":"10.1016\/j.prp.2023.154988_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4291\/wjgp.v13.i1.15","article-title":"Current treatment strategies and future perspectives for gastrointestinal stromal tumors","volume":"13","author":"Sugiyama","year":"2022","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"10.1016\/j.prp.2023.154988_bib15","doi-asserted-by":"crossref","unstructured":"M. Ashrafizadeh et al., Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response. (2023).","DOI":"10.1002\/med.21950"},{"key":"10.1016\/j.prp.2023.154988_bib16","first-page":"249","article-title":"Epidemiology of gastrointestinal and liver tumors","volume":"14","author":"Herszenyi","year":"2010","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.prp.2023.154988_bib17","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1002\/cncr.30239","article-title":"Diagnostic and treatment strategy for small gastrointestinal stromal tumors","volume":"122","author":"Nishida","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.21037\/jgo.2018.08.20","article-title":"Gastrointestinal stromal tumors: a comprehensive review","volume":"10","author":"Parab","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib19","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3748\/wjg.v24.i26.2806","article-title":"Current clinical management of gastrointestinal stromal tumor","volume":"24","author":"Akahoshi","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.prp.2023.154988_bib20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/9781119196235.ch32","article-title":"Gastrointestinal stromal tumors","author":"von Mehren","year":"2017","journal-title":"Textb. Uncommon Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.21037\/jgo.2016.05.06","article-title":"Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review","volume":"7","author":"Verma","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib22","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/cancers13051172","article-title":"Cancer-associated fibroblast-induced resistance to chemotherapy and radiotherapy in gastrointestinal cancers","volume":"13","author":"Ham","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154988_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctcp.2021.101527","article-title":"Moxibustion for alleviating chemotherapy-induced gastrointestinal adverse effects: a systematic review of randomized controlled trials","author":"Yao","year":"2022","journal-title":"Complement. Ther. Clin. Pract."},{"key":"10.1016\/j.prp.2023.154988_bib24","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.3390\/cancers13143525","article-title":"Immunotherapy strategies for gastrointestinal stromal tumor","volume":"13","author":"Arshad","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154988_bib25","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.3389\/fphar.2022.922029","article-title":"Ginsenosides: Allies of gastrointestinal tumor immunotherapy","volume":"13","author":"Feng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2023.154988_bib26","article-title":"Epigenetic regulation of autophagy by non-coding RNAs in gastrointestinal tumors: Biological functions and therapeutic perspectives","author":"Zandieh","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prp.2023.154988_bib27","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.3389\/fonc.2021.822745","article-title":"Interaction of ncRNA and epigenetic modifications in gastric cancer: focus on histone modification","volume":"11","author":"Yang","year":"2022","journal-title":"Front. Oncol."},{"issue":"106311 (","key":"10.1016\/j.prp.2023.154988_bib28","article-title":"STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response","author":"Sadrkhanloo","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prp.2023.154988_bib29","article-title":"The role of circadian gene timeless in gastrointestinal cancers","author":"Hosseini","year":"2022","journal-title":"Gene Rep."},{"key":"10.1016\/j.prp.2023.154988_bib30","doi-asserted-by":"crossref","unstructured":"B. Xie et al., KAT8-catalyzed lactylation contributes to eEF1A2-mediated protein synthesis and colorectal carcinogenesis. (2022).","DOI":"10.21203\/rs.3.rs-2177254\/v1"},{"key":"10.1016\/j.prp.2023.154988_bib31","article-title":"Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours","volume":"8","author":"Garg","year":"2022","journal-title":"Future J. Pharm. Sci."},{"key":"10.1016\/j.prp.2023.154988_bib32","article-title":"Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration","author":"Van","year":"2022","journal-title":"OpenNano"},{"key":"10.1016\/j.prp.2023.154988_bib33","series-title":"Seminars in Oncology","author":"Shin","year":"2022"},{"key":"10.1016\/j.prp.2023.154988_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/aps.2013.161","article-title":"EZH2: biology, disease, and structure-based drug discovery","volume":"35","author":"Tan","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.prp.2023.154988_bib35","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1080\/15384101.2022.2092819","article-title":"BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer","volume":"21","author":"Chen","year":"2022","journal-title":"Cell Cycle"},{"key":"10.1016\/j.prp.2023.154988_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/15592294.2019.1570771","article-title":"Paternal genome rescues mouse preimplantation embryo development in the absence of maternally-recruited EZH2 activity","volume":"14","author":"Wang","year":"2019","journal-title":"Epigenetics"},{"key":"10.1016\/j.prp.2023.154988_bib37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1530\/ERC-13-0497","article-title":"The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors","volume":"21","author":"Svedlund","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib38","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.18632\/oncotarget.2262","article-title":"EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer","volume":"5","author":"Chinaranagari","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154988_bib39","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nchembio.1331","article-title":"Targeted disruption of the EZH2\u2013EED complex inhibits EZH2-dependent cancer","volume":"9","author":"Kim","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.prp.2023.154988_bib40","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-10-2156","article-title":"Aberrations of EZH2 in CancerAberrations of EZH2 in Cancer","volume":"17","author":"Chase","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib41","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/2159-8290.CD-22-0329","article-title":"Epigenetic Regulation to Enhance Graft-versus-Leukemia Activity","volume":"12","author":"K\u00f6hler","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2023.154988_bib42","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1038\/s41375-020-0816-y","article-title":"Mutational mechanisms of EZH2 inactivation in myeloid neoplasms","volume":"34","author":"Chase","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2023.154988_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-37699-w","article-title":"The EZH2 SANT1 domain is a histone reader providing sensitivity to the modification state of the H4 tail","volume":"9","author":"Weaver","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2023.154988_bib44","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10565-019-09471-x","article-title":"Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1\/2 signaling","volume":"35","author":"Hu","year":"2019","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.prp.2023.154988_bib45","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/0008-5472.CAN-15-1141","article-title":"Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene MutationsOncogenic KRAS Modulates EZH2 Expression in NSCLC","volume":"76","author":"Riquelme","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib46","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/biof.1634","article-title":"New insights into the core Hippo signaling and biological macromolecules interactions in the biology of solid tumors","volume":"46","author":"Mohammadi","year":"2020","journal-title":"Biofactors"},{"key":"10.1016\/j.prp.2023.154988_bib47","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1007\/s11033-023-08530-1","article-title":"Long non-coding RNA SNHG17 contributes to the progression of pancreatic adenocarcinoma by modulating miR-32-5p\/EZH2\/STAT3 signaling","volume":"50","author":"Ying","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.prp.2023.154988_bib48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.yexcr.2018.02.037","article-title":"MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2\u2013STAT3 signaling axis","volume":"366","author":"Ma","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12935-020-01620-1","article-title":"LINC00152 upregulates ZEB1 expression and enhances epithelial-mesenchymal transition and oxaliplatin resistance in esophageal cancer by interacting with EZH2","volume":"20","author":"Zhang","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2023.154988_bib50","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1078-0432.CCR-16-2248","article-title":"STAT3\/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent MannerSTAT3\/HOTAIR\/EZH2 Regulates HNSCC Growth","volume":"24","author":"Sun","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib51","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1139\/bcb-2019-0446","article-title":"LINP1 promotes the progression of cervical cancer by scaffolding EZH2, LSD1, and DNMT1 to inhibit the expression of KLF2 and PRSS8","volume":"98","author":"Wu","year":"2020","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.prp.2023.154988_bib52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1541-7786.MCR-12-0661","article-title":"NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells","volume":"11","author":"Garipov","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1340-7","article-title":"ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p\/LASP1 signaling axis","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib54","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/pros.20550","article-title":"EZH2 promotes proliferation and invasiveness of prostate cancer cells","volume":"67","author":"Bryant","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.prp.2023.154988_bib55","volume":"146","author":"Paskeh","year":"2022","journal-title":"EZH2 a N. Ther. Target. brain Tumor.: Mol. Landsc., Ther. Target. Future Prospects"},{"key":"10.1016\/j.prp.2023.154988_bib56","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1016\/j.bmcl.2015.06.056","article-title":"Discovery, design, and synthesis of indole-based EZH2 inhibitors","volume":"25","author":"Gehling","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.prp.2023.154988_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113274","article-title":"Applications of resveratrol in the treatment of gastrointestinal cancer","volume":"153","author":"Roshani","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2023.154988_bib58","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/carcin\/bgx065","article-title":"Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression","volume":"38","author":"Yoshida","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.prp.2023.154988_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review","volume":"2022","author":"Mer\u0107ep","year":"2022","journal-title":"Cardiovasc Ther."},{"key":"10.1016\/j.prp.2023.154988_bib60","doi-asserted-by":"crossref","DOI":"10.32628\/IJSRST218422","article-title":"Modern Developments of Nano Based Drug Delivery System by Combined with Phytochemicals- Presenting New Aspects","author":"Nath","year":"2021","journal-title":"Int. J. Sci. Res. Sci. Technol."},{"key":"10.1016\/j.prp.2023.154988_bib61","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ijbiomac.2022.10.196","article-title":"TGF-\u03b21 suppresses de novo cholesterol biosynthesis in granulosa-lutein cells by down-regulating DHCR24 expression via the GSK-3\u03b2\/EZH2\/H3K27me3 signaling pathway","volume":"224","author":"Li","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.prp.2023.154988_bib62","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.3390\/cancers14143451","article-title":"TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer","volume":"14","author":"Versemann","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154988_bib63","first-page":"1","article-title":"UHRF1\/UBE2L6\/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma","author":"Kuser-Abali","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2023.154988_bib64","doi-asserted-by":"crossref","first-page":"8658","DOI":"10.1039\/D0TB01177K","article-title":"A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy","volume":"8","author":"Kaundal","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.prp.2023.154988_bib65","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.biomaterials.2017.11.014","article-title":"Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo","volume":"155","author":"Yu","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.prp.2023.154988_bib66","unstructured":"R. Alwi et al., in Biomedical optics. (2013)."},{"key":"10.1016\/j.prp.2023.154988_bib67","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/RLI.0000000000000946","article-title":"Multimodal in vivo tracking of chimeric antigen receptor T cells in preclinical glioblastoma models","volume":"58","author":"Wu","year":"2023","journal-title":"Investig. Radio."},{"key":"10.1016\/j.prp.2023.154988_bib68","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11307-016-1001-6","article-title":"Targeted superparamagnetic iron oxide nanoparticles for in vivo magnetic resonance imaging of T-cells in rheumatoid arthritis","volume":"19","author":"Chen","year":"2017","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.prp.2023.154988_bib69","doi-asserted-by":"crossref","first-page":"10214","DOI":"10.1021\/acsnano.5b03902","article-title":"Cuboplexes: Topologically Active siRNA Delivery","volume":"9","author":"Kim","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.prp.2023.154988_bib70","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.prp.2023.154988_bib71","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/IJN.S340926","article-title":"Dual pH-Responsive and Tumor-Targeted Nanoparticle-Mediated Anti-Angiogenesis siRNA Delivery for Tumor Treatment","volume":"17","author":"Zhang","year":"2022","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.prp.2023.154988_bib72","first-page":"35","article-title":"Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment","volume":"1","author":"Guo","year":"2021","journal-title":"Explor. (Beijing)"},{"key":"10.1016\/j.prp.2023.154988_bib73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00535-009-0151-6","article-title":"Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human digestive\/gastrointestinal cancers","volume":"45","author":"Wang","year":"2010","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.prp.2023.154988_bib74","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.14309\/00000434-201710001-00297","article-title":"Preclinical and clinical studies on safety of CEQ508 bacteria engineered to deliver short-hairpin RNA to mediate RNA interference against \u03b2-catenin in the GI tract of patients with familial adenomatous polyposis: 297","volume":"112","author":"D'Cruz","year":"2017","journal-title":"Off. J. Am. Coll. Gastroenterol. | ACG"},{"key":"10.1016\/j.prp.2023.154988_bib75","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-022-01235-1","article-title":"The long and short non-coding RNAs modulating EZH2 signaling in cancer","volume":"15","author":"Mirzaei","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-01173-x","article-title":"Verification of EZH2 as a druggable target in metastatic uveal melanoma","volume":"19","author":"Jin","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib77","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1172\/JCI90793","article-title":"CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2","volume":"128","author":"Chen","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.prp.2023.154988_bib78","first-page":"358","article-title":"Construction of EZH2 Knockout Animal Model by CRISPR\/Cas9 Technology. Zhongguo fei ai za zhi= Chinese Journal of Lung Cancer","volume":"21","author":"Meng","year":"2018"},{"key":"10.1016\/j.prp.2023.154988_bib79","first-page":"2870","article-title":"HIF1\u03b1 epigenetically repressed macrophages via CRISPR\/Cas9-EZH2 system for enhanced cancer immunotherapy","volume":"6","author":"Dong","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.prp.2023.154988_bib80","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/tcr.201800091","article-title":"Six years (2012\u20132018) of researches on catalytic ezh2 inhibitors: the boom of the 2\u2013pyridone compounds","volume":"18","author":"Fioravanti","year":"2018","journal-title":"Chem. Rec."},{"key":"10.1016\/j.prp.2023.154988_bib81","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/CAD.0000000000000166","article-title":"S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells","volume":"26","author":"Liu","year":"2015","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.prp.2023.154988_bib82","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.prp.2023.154988_bib83","first-page":"1561","article-title":"Effects of H3K27 methylation inhibitor EPZ005687 on apoptosis, proliferation and cell cycle of U937 cells and normal CD34 positive cells","volume":"22","author":"Tang","year":"2014","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"10.1016\/j.prp.2023.154988_bib84","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9174926","article-title":"EZH2 inhibition ameliorates transverse aortic constriction-induced pulmonary arterial hypertension in mice","volume":"2018","author":"Shi","year":"2018","journal-title":"Can. Respir. J."},{"key":"10.1016\/j.prp.2023.154988_bib85","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-18-2395","article-title":"EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cellsGSK126 dampens antitumor immunity","volume":"79","author":"Huang","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib86","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.prp.2023.154988_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109389","article-title":"The role of EZH2 as a potential therapeutic target in retinoblastoma","author":"Zhao","year":"2023","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.prp.2023.154988_bib88","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/med.21870","article-title":"Salinomycin as a potent anticancer stem cell agent: State of the art and future directions","volume":"42","author":"Qi","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.prp.2023.154988_bib89","doi-asserted-by":"crossref","unstructured":"B. Verdoodt\u00a0et al. Sali induces autophagy Colon Breast Cancer Cells concomitant Gener. React. Oxyg. Species 2012.","DOI":"10.1371\/journal.pone.0044132"},{"key":"10.1016\/j.prp.2023.154988_bib90","doi-asserted-by":"crossref","first-page":"10167","DOI":"10.1021\/acs.jmedchem.1c00460","article-title":"Design, synthesis, and evaluation of VHL-based EZH2 degraders to enhance therapeutic activity against lymphoma","volume":"64","author":"Tu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.prp.2023.154988_bib91","article-title":"Targeting EZH2 for cancer therapy: From current progress to novel strategies","author":"Zeng","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.prp.2023.154988_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chembiol.2019.11.004","article-title":"EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex","volume":"27","author":"Hsu","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.prp.2023.154988_bib93","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40291-021-00573-z","article-title":"Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension","volume":"26","author":"Yasuhara","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.prp.2023.154988_bib94","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med Chem. Lett."},{"key":"10.1016\/j.prp.2023.154988_bib95","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib96","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1039\/D2NP00038E","article-title":"Natural product-based PROteolysis TArgeting Chimeras (PROTACs)","volume":"39","author":"Liu","year":"2022","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.prp.2023.154988_bib97","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40259-022-00551-9","article-title":"PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras","volume":"36","author":"Madan","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.prp.2023.154988_bib98","article-title":"EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. Biomedicine &","volume":"146","author":"Paskeh","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib99","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12967-021-02789-3","article-title":"Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo\/Gli-1 pathway in acute myeloid leukemia","volume":"19","author":"Jiang","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2023.154988_bib100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jcpt.12759","article-title":"Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead","volume":"44","author":"Shah","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.prp.2023.154988_bib101","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3892\/ijmm.2014.1724","article-title":"Delivery of EZH2-shRNA with mPEG-PEI nanoparticles for the treatment of prostate cancer in vitro","volume":"33","author":"Wu","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.prp.2023.154988_bib102","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib103","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib104","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.prp.2023.154988_bib105","first-page":"158","article-title":"Tazemetostat: EZH2 Inhibitor","volume":"13","author":"Straining","year":"2022","journal-title":"J. Adv. Pr. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib106","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.ejca.2005.01.028","article-title":"Improvement in colorectal cancer survival: a population-based study","volume":"41","author":"Mitry","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib107","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/0008-5472.CAN-14-2240","article-title":"Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes","volume":"75","author":"Linnekamp","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib108","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.prp.2023.154988_bib109","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.biopha.2014.10.019","article-title":"Colon cancer: cancer stem cells markers, drug resistance and treatment","volume":"68","author":"Kozovska","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2023.154988_bib110","article-title":"A systematic analysis of the global and regional burden of colon and rectum cancer and the difference between early-and late-onset CRC from 1990 to 2019","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib111","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fonc.2013.00326","article-title":"Functions and regulation of the PTEN gene in colorectal cancer","volume":"3","author":"Molinari","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib112","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3390\/cancers11111765","article-title":"PTEN in colorectal cancer: shedding light on its role as predictor and target","volume":"11","author":"Salvatore","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154988_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.646217","article-title":"LINC00470 stimulates methylation of PTEN to facilitate the progression of endometrial cancer by recruiting DNMT3a through MYC","volume":"11","author":"Yi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-030-02771-1_5","article-title":"Targeting PTEN in colorectal cancers","author":"Kotelevets","year":"2018","journal-title":"Target. Ther. Colorectal Cancer Subtypes"},{"key":"10.1016\/j.prp.2023.154988_bib115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biopha.2018.05.015","article-title":"The protective role of all-transretinoic acid (ATRA) against colorectal cancer development is achieved via increasing miR-3666 expression and decreasing E2F7 expression. Biomedicine &","volume":"104","author":"Liu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.prp.2023.154988_bib116","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1038\/sj.onc.1206004","article-title":"Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells","volume":"21","author":"Real","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2023.154988_bib117","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10495-020-01601-9","article-title":"BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy","volume":"25","author":"Ramesh","year":"2020","journal-title":"Apoptosis"},{"key":"10.1016\/j.prp.2023.154988_bib118","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3892\/ijo.2014.2259","article-title":"The IL-6\/JAK\/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer","volume":"44","author":"Wang","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib119","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3390\/biomedicines9081016","article-title":"Targeting STAT3 signaling pathway in colorectal cancer","volume":"9","author":"Gargalionis","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2023.154988_bib120","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/leu.2010.311","article-title":"EZH2 Y641 mutations in follicular lymphoma","volume":"25","author":"B\u00f6d\u00f6r","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2023.154988_bib121","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/onc.2013.571","article-title":"Oncogenic Y641 mutations in EZH2 prevent Jak2\/\u03b2-TrCP-mediated degradation","volume":"34","author":"Sahasrabuddhe","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2023.154988_bib122","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.biocel.2019.05.011","article-title":"LncRNA H19 promotes epithelial mesenchymal transition and metastasis of esophageal cancer via STAT3\/EZH2 axis","volume":"113","author":"Chen","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.prp.2023.154988_bib123","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/path.4179","article-title":"Retracted: Role of STAT3 and vitamin D receptor in EZH2\u2013mediated invasion of human colorectal cancer","volume":"230","author":"Lin","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.prp.2023.154988_bib124","first-page":"681","article-title":"Interplay between SOX9 transcription factor and microRNAs in cancer","volume":"183","author":"Ashrafizadeh","year":"2021"},{"key":"10.1016\/j.prp.2023.154988_bib125","doi-asserted-by":"crossref","unstructured":"S. Mirzaei\u00a0et al. role Micro -338-3p Cancer.: Growth, Invasion, chemoresistance, Mediat. 268 2021 119005.","DOI":"10.1016\/j.lfs.2020.119005"},{"key":"10.1016\/j.prp.2023.154988_bib126","doi-asserted-by":"crossref","unstructured":"M. Ashrafizadeh\u00a0et al. Lung Cancer Cells their Sensit. \/Resist. cisplatin Chemother.: role Micro upstream Mediat. 78 2021 109871.","DOI":"10.1016\/j.cellsig.2020.109871"},{"key":"10.1016\/j.prp.2023.154988_bib127","article-title":"miR-139-5p inhibits the epithelial-mesenchymal transition and enhances the chemotherapeutic sensitivity of colorectal cancer cells by downregulating BCL2","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2023.154988_bib128","first-page":"868","article-title":"EZH2-mediated microRNA-139-5p regulates epithelial-mesenchymal transition and lymph node metastasis of pancreatic cancer","volume":"41","author":"Ma","year":"2018","journal-title":"Mol. Cells"},{"key":"10.1016\/j.prp.2023.154988_bib129","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-017-0008-4","article-title":"Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p","volume":"6","author":"Bian","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.prp.2023.154988_bib130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41388-018-0435-5","article-title":"O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc\/EZH2 regulatory feedback circuit","volume":"38","author":"Jiang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2023.154988_bib131","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s13577-021-00494-3","article-title":"ERO1\u03b1 mediates endoplasmic reticulum stress-induced apoptosis via microRNA-101\/EZH2 axis in colon cancer RKO and HT-29 cells","volume":"34","author":"Wang","year":"2021","journal-title":"Hum. Cell"},{"key":"10.1016\/j.prp.2023.154988_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-12-505","article-title":"Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer","volume":"12","author":"Schee","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260103","article-title":"H19-and hsa-miR-338-3p-mediated NRP1 expression is an independent predictor of poor prognosis in glioblastoma","volume":"16","author":"Liu","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.prp.2023.154988_bib134","first-page":"2256","article-title":"miR-338-3p suppresses colorectal cancer proliferation and progression by inhibiting MACC1","volume":"11","author":"Zou","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.prp.2023.154988_bib135","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/cam4.2105","article-title":"Lnc RNA\u2010SNHG 15 enhances cell proliferation in colorectal cancer by inhibiting miR\u2010338\u20133p","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.prp.2023.154988_bib136","article-title":"MicroRNAs and the PTEN\/PI3K\/Akt pathway in gastric cancer","author":"Hu","year":"2019","journal-title":"Oncol. Rep. 41, 1439-1454"},{"key":"10.1016\/j.prp.2023.154988_bib137","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-018-0028-8","article-title":"Inhibition of ATG12-mediated autophagy by miR-214 enhances radiosensitivity in colorectal cancer","volume":"7","author":"Hu","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/j.prp.2023.154988_bib138","first-page":"214","volume":"41","author":"Mirzaei","year":"2022","journal-title":"Mol. Landsc. LncRNAs Prostate Cancer.: A Focus Pathw. Ther. Targets Interv."},{"key":"10.1016\/j.prp.2023.154988_bib139","doi-asserted-by":"crossref","unstructured":"M. Entezari\u00a0et al. Long. Non-coding RNAs exosomal lncRNAs: Potential Funct. lung Cancer Progress., Drug Resist. Tumor Microenviron. Remodel. 150 2022 112963.","DOI":"10.1016\/j.biopha.2022.112963"},{"key":"10.1016\/j.prp.2023.154988_bib140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.18632\/oncotarget.2681","article-title":"Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154988_bib141","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1002\/jcb.27893","article-title":"Hotair mediates tumorigenesis through recruiting EZH2 in colorectal cancer","volume":"120","author":"Huang","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.prp.2023.154988_bib142","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1158\/0008-5472.CAN-11-1021","article-title":"Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers","volume":"71","author":"Kogo","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib143","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/cancers10110440","article-title":"Epigenetic regulation by lncRNAs: an overview focused on UCA1 in colorectal cancer","volume":"10","author":"Neve","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154988_bib144","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.prp.2018.07.036","article-title":"LncRNA UCA1 sponges miR-204-5p to promote migration, invasion and epithelial-mesenchymal transition of glioma cells via upregulation of ZEB1","volume":"214","author":"Liang","year":"2018","journal-title":"Pathol. -Res. Pract."},{"key":"10.1016\/j.prp.2023.154988_bib145","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.7150\/thno.38507","article-title":"MicroRNA-204-5p is a tumor suppressor and potential therapeutic target in head and neck squamous cell carcinoma","volume":"10","author":"Zhuang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2023.154988_bib146","doi-asserted-by":"crossref","unstructured":"W.-W. Xu, J. Jin, X.-y Wu, Q.-L. Ren, M. Farzaneh, MALAT1-related signaling pathways in colorectal cancer. Cancer Cell International 22, 1\u20139 (2022).","DOI":"10.1186\/s12935-022-02540-y"},{"key":"10.1016\/j.prp.2023.154988_bib147","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1158\/1535-7163.MCT-16-0591","article-title":"MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2023.154988_bib148","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41419-019-1742-7","article-title":"Long noncoding RNA Neat1 modulates myogenesis by recruiting Ezh2","volume":"10","author":"Wang","year":"2019","journal-title":"Cell death Dis."},{"key":"10.1016\/j.prp.2023.154988_bib149","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41419-020-03164-8","article-title":"LncRNA NEAT1 remodels chromatin to promote the 5-Fu resistance by maintaining colorectal cancer stemness","volume":"11","author":"Zhu","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12935-022-02627-6","article-title":"Emerging roles for lncRNA-NEAT1 in colorectal cancer","volume":"22","author":"Azizidoost","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2023.154988_bib151","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.canlet.2013.01.033","article-title":"Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression","volume":"333","author":"Luo","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2023.154988_bib152","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ebiom.2016.11.001","article-title":"Biological and Clinical Relevance of H19 in Colorectal Cancer Patients","volume":"13","author":"Schwarzenbach","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.prp.2023.154988_bib153","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1158\/0008-5472.CAN-07-5805","article-title":"Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells","volume":"68","author":"Darido","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib154","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12967-022-03521-5","article-title":"SOX21-AS1 activated by STAT6 promotes pancreatic cancer progression via up-regulation of SOX21","volume":"20","author":"Yu","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2023.154988_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.637298","article-title":"The role of KDM2B and EZH2 in regulating the stemness in colorectal cancer through the PI3K\/AKT pathway","volume":"11","author":"Sanches","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib156","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1080\/15548627.2015.1117734","article-title":"Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway","volume":"11","author":"Wei","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.prp.2023.154988_bib157","first-page":"324","article-title":"S6K1 controls adiponectin expression by inducing a transcriptional switch: BMAL1-to-EZH2. Experimental &","volume":"54","author":"Yi","year":"2022","journal-title":"Mol. Med."},{"key":"10.1016\/j.prp.2023.154988_bib158","doi-asserted-by":"crossref","first-page":"16143","DOI":"10.3390\/ijms232416143","article-title":"Nuclear S6K1 Enhances Oncogenic Wnt Signaling by Inducing Wnt\/\u03b2-Catenin Transcriptional Complex Formation","volume":"23","author":"Lee","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154988_bib159","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.molcel.2021.03.009","article-title":"mTORC1 stimulates cell growth through SAM synthesis and m6A mRNA-dependent control of protein synthesis","volume":"81","author":"Villa","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.prp.2023.154988_bib160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9969","article-title":"Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma","volume":"9","author":"Oricchio","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.prp.2023.154988_bib161","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.7314\/APJCP.2013.14.4.2201","article-title":"Potential targets for prevention of colorectal cancer: a focus on PI3K\/Akt\/mTOR and Wnt pathways","volume":"14","author":"Pandurangan","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.prp.2023.154988_bib162","first-page":"1661","article-title":"EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cells","volume":"6","author":"Hsieh","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib163","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","article-title":"Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition","volume":"23","author":"Rizq","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2023.154988_bib164","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/pbi.13838","article-title":"Genome-wide analyses of PAM-relaxed Cas9 genome editors reveal substantial off-target effects by ABE8e in rice","volume":"20","author":"Wu","year":"2022","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.prp.2023.154988_bib165","doi-asserted-by":"crossref","first-page":"7853","DOI":"10.2147\/OTT.S180131","article-title":"EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression","author":"Wang","year":"2018","journal-title":"OncoTargets Ther."},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib166","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-021-07978-3","article-title":"The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity","volume":"21","author":"Ge","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib167","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.7150\/thno.41219","article-title":"ATRX\/EZH2 complex epigenetically regulates FADD\/PARP1 axis, contributing to TMZ resistance in glioma","volume":"10","author":"Han","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2023.154988_bib168","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1111\/jcmm.14593","article-title":"LINC01303 functions as a competing endogenous RNA to regulate EZH2 expression by sponging miR\u2010101\u20133p in gastric cancer","volume":"23","author":"Cao","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.prp.2023.154988_bib169","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1158\/0008-5472.CAN-16-2964","article-title":"TET-mediated sequestration of miR-26 drives EZH2 expression and gastric carcinogenesis","volume":"77","author":"Deng","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib170","first-page":"4232","article-title":"Long noncoding RNA LINC00511 promoted cell proliferation and invasion via regulating miR-124-3p\/EZH2 pathway in gastric cancer","volume":"24","author":"Huang","year":"2020","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.prp.2023.154988_bib171","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/path.4032","article-title":"Lack of microRNA\u2010101 causes E\u2010cadherin functional deregulation through EZH2 up\u2010regulation in intestinal gastric cancer","volume":"228","author":"Carvalho","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.prp.2023.154988_bib172","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2014.17","article-title":"Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells","volume":"3","author":"Hibino","year":"2014","journal-title":"Oncogenesis"},{"key":"10.1016\/j.prp.2023.154988_bib173","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.3748\/wjg.v23.i33.6100","article-title":"HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer","volume":"23","author":"Chen","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.prp.2023.154988_bib174","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jb\/mvz097","article-title":"LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2","volume":"167","author":"Zhou","year":"2020","journal-title":"J. Biochem."},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12935-020-01167-1","article-title":"Long non-coding RNA GAS5 accelerates oxidative stress in melanoma cells by rescuing EZH2-mediated CDKN1C downregulation","volume":"20","author":"Xu","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2023.154988_bib176","doi-asserted-by":"crossref","first-page":"43997","DOI":"10.18632\/oncotarget.9766","article-title":"BET inhibition as a new strategy for the treatment of gastric cancer","volume":"7","author":"Montenegro","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154988_bib177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-019-0762-x","article-title":"BET and EZH2 inhibitors: novel approaches for targeting cancer","volume":"21","author":"Genta","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.prp.2023.154988_bib178","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.7314\/APJCP.2015.16.6.2425","article-title":"siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells","volume":"16","author":"Zhou","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.prp.2023.154988_bib179","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.143","article-title":"Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Cell death Dis."},{"key":"10.1016\/j.prp.2023.154988_bib180","first-page":"3238","article-title":"Long noncoding RNA LINC00337 promote gastric cancer proliferation through repressing p21 mediated by EZH2. American Journal of Translational Research","volume":"11","author":"Hu","year":"2019"},{"key":"10.1016\/j.prp.2023.154988_bib181","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-021-01365-z","article-title":"The role and application of small extracellular vesicles in gastric cancer","volume":"20","author":"Wu","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib182","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.neo.2021.06.007","article-title":"EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201\/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG","volume":"23","author":"Zhang","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.prp.2023.154988_bib183","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.2147\/OTT.S237474","article-title":"Diosgenin and GSK126 produce synergistic effects on epithelial\u2013mesenchymal transition in gastric cancer cells by mediating EZH2 via the Rho\/ROCK signaling pathway","volume":"13","author":"Liu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.prp.2023.154988_bib184","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73525-y","article-title":"The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data","volume":"10","author":"Bengtsson","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2023.154988_bib185","doi-asserted-by":"crossref","unstructured":"S. Mirzaei\u00a0et al. Pre-Clin. Clin. Appl. small Interf. RNAs (siRNA) Co. -Deliv. Syst. Pancreat. Cancer Ther. 10 2021 3348.","DOI":"10.3390\/cells10123348"},{"key":"10.1016\/j.prp.2023.154988_bib186","doi-asserted-by":"crossref","unstructured":"M. Ashrafizadeh et al., Long noncoding RNAs (lncRNAs) in pancreatic cancer progression. (2022).","DOI":"10.1016\/j.drudis.2022.05.012"},{"key":"10.1016\/j.prp.2023.154988_bib187","first-page":"449","volume":"vol. 54","author":"Cubilla","year":"1979","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.prp.2023.154988_bib188","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.surg.2012.05.020","article-title":"Pancreatic ductal adenocarcinoma: long-term survival does not equal cure","volume":"152","author":"Ferrone","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.prp.2023.154988_bib189","article-title":"Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography","volume":"14","author":"Ren","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2023.154988_bib190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-020-00184-0","article-title":"Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma","volume":"9","author":"Gao","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib191","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.3390\/cancers13174434","article-title":"Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress","volume":"13","author":"Mehra","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154988_bib192","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/s41416-020-0997-1","article-title":"Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer","volume":"123","author":"Iwatate","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib193","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3390\/cancers14040973","article-title":"The Role of SMAD4 Inactivation in Epithelial\u2013Mesenchymal Plasticity of Pancreatic Ductal Adenocarcinoma: The Missing Link?","volume":"14","author":"Racu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154988_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108107","article-title":"Targeting hedgehog signaling in pancreatic ductal adenocarcinoma","author":"Quatannens","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.prp.2023.154988_bib195","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8604340","article-title":"MCM2 and NUSAP1 are potential biomarkers for the diagnosis and prognosis of pancreatic cancer","volume":"2020","author":"Deng","year":"2020","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.prp.2023.154988_bib196","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.3390\/cancers14153674","article-title":"Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes","volume":"14","author":"Tsumura","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154988_bib197","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100121RRR","article-title":"Caveolin\u20101 increases glycolysis in pancreatic cancer cells and triggers cachectic states","volume":"35","author":"Hu","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.prp.2023.154988_bib198","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.18632\/oncotarget.1842","article-title":"Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth","volume":"5","author":"Vincent","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154988_bib199","doi-asserted-by":"crossref","first-page":"84153","DOI":"10.18632\/oncotarget.20359","article-title":"Long non-coding RNA SNHG15 inhibits P15 and KLF2 expression to promote pancreatic cancer proliferation through EZH2-mediated H3K27me3","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154988_bib200","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200143119","article-title":"Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer","volume":"119","author":"Principe","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2023.154988_bib201","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5966\/sctm.2012-0036","article-title":"EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter","volume":"2","author":"van Vlerken","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.prp.2023.154988_bib202","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1535-7163.MCT-12-0037","article-title":"Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer CellsDZNeP\/Gemcitabine Combination in Pancreatic Cancer","volume":"11","author":"Avan","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2023.154988_bib203","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2010.05.003","article-title":"RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo","volume":"297","author":"Chen","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2023.154988_bib204","article-title":"High vs. low radiation dose of concurrent chemoradiotherapy for esophageal carcinoma with modern radiotherapy techniques: a meta-analysis","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib205","article-title":"Cellular origins of regenerating liver and hepatocellular carcinoma","volume":"4","author":"Holczbauer","year":"2022","journal-title":"JHEP Rep."},{"key":"10.1016\/j.prp.2023.154988_bib206","doi-asserted-by":"crossref","unstructured":"M. Deldar Abad Paskeh, S. Mirzaei, M. Ashrafizadeh, A. Zarrabi, G.J.J. o H.C. Sethi, Wnt\/\u03b2-catenin signaling as a driver of hepatocellular carcinoma progression: An emphasis on molecular pathways. 1415\u20131444 (2021).","DOI":"10.2147\/JHC.S336858"},{"key":"10.1016\/j.prp.2023.154988_bib207","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1245\/s10434-022-13063-1","article-title":"ASO Author Reflections: The Prognostic Value of Preoperative Serum Markers and Risk Classification of Patients With Hepatocellular Carcinoma","volume":"30","author":"Ota","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib208","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00261-017-1209-1","article-title":"Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis","volume":"43","author":"Tang","year":"2018","journal-title":"Abdom. Radiol."},{"key":"10.1016\/j.prp.2023.154988_bib209","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5114\/wo.2018.78941","article-title":"Update in global trends and aetiology of hepatocellular carcinoma","volume":"22","author":"Rawla","year":"2018","journal-title":"Contemp. Oncol. \/Wsp\u00f3\u0142czesna Onkol."},{"key":"10.1016\/j.prp.2023.154988_bib210","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.3390\/jcm10194315","article-title":"Management of liver tumors during the COVID-19 pandemic: The added value of selective internal radiation therapy (SIRT)","volume":"10","author":"Bargellini","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.prp.2023.154988_bib211","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/fon.14.218","article-title":"The effectiveness of selective internal radiation therapy in challenging cases of liver-predominant unresectable hepatocellular carcinoma","volume":"10","author":"Malfertheiner","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib212","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-05764-6","article-title":"Retraction Note: Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer","volume":"14","author":"Tan","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.prp.2023.154988_bib213","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41417-019-0117-7","article-title":"Targeting mTOR suppressed colon cancer growth through 4EBP1\/eIF4E\/PUMA pathway","volume":"27","author":"Wang","year":"2020","journal-title":"Cancer gene Ther."},{"key":"10.1016\/j.prp.2023.154988_bib214","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1245\/s10434-014-3779-2","article-title":"Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma","volume":"21","author":"Yamada","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib215","first-page":"422","article-title":"EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2\/-9 pathway","volume":"8","author":"Chien","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib216","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3390\/genes13050876","article-title":"High expression of Ezh2 mediated by ncrnas correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma","volume":"13","author":"Chen","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.prp.2023.154988_bib217","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819879905","article-title":"Cancer-associated fibroblasts promote angiogenesis of hepatocellular carcinoma by VEGF-mediated EZH2\/VASH1 pathway","volume":"18","author":"Huang","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.prp.2023.154988_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188700","article-title":"EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy","author":"Sun","year":"2022","journal-title":"Biochim. Et. Biophys. Acta (BBA)-Rev. Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110068","article-title":"Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma","volume":"118","author":"Qiang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.prp.2023.154988_bib220","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1158\/1541-7786.MCR-17-0105","article-title":"MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and DifferentiationInteraction between MELK and EZH2 in Medulloblastoma","volume":"15","author":"Liu","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib221","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7608712","article-title":"Dysregulation of Ezh2\/Mir-138-5p axis contributes to radiosensitivity in hepatocellular carcinoma cell by downregulating hypoxia-inducible factor 1 alpha (Hif-1\u03b1)","volume":"2022","author":"Bai","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.prp.2023.154988_bib222","doi-asserted-by":"crossref","first-page":"E3509","DOI":"10.1073\/pnas.1802691115","article-title":"Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells","volume":"115","author":"Bugide","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2023.154988_bib223","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00889-0","article-title":"EZH1\/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma","volume":"11","author":"Kusakabe","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2023.154988_bib224","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3892\/or.2015.4467","article-title":"Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma","volume":"35","author":"Huang","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.prp.2023.154988_bib225","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jhep.2013.10.028","article-title":"MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity","volume":"60","author":"Xu","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.prp.2023.154988_bib226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0690-5","article-title":"lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a\/b and miR-214 in colorectal cancer","volume":"12","author":"Xu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib227","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41374-019-0270-5","article-title":"miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2","volume":"99","author":"Zhao","year":"2019","journal-title":"Lab. Investig."},{"key":"10.1016\/j.prp.2023.154988_bib228","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ebiom.2018.08.055","article-title":"LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation","volume":"36","author":"Cheng","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.prp.2023.154988_bib229","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1440-1746.2011.07049.x","article-title":"Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma","volume":"27","author":"Zhang","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.prp.2023.154988_bib230","first-page":"1695","article-title":"Circular RNA circ-ADD3 inhibits hepatocellular carcinoma metastasis through facilitating EZH2 degradation via CDK1-mediated ubiquitination","volume":"9","author":"Sun","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib231","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00268-004-7542-x","article-title":"Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma","volume":"29","author":"Mariette","year":"2005","journal-title":"World J. Surg."},{"key":"10.1016\/j.prp.2023.154988_bib232","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/cbin.11991","article-title":"Human umbilical cord mesenchymal stem cells: Heralding an effective treatment against esophageal cancer?","volume":"47","author":"ArefNezhad","year":"2023","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.prp.2023.154988_bib233","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3390\/cancers12061592","article-title":"Distribution of lymph node metastases in esophageal carcinoma patients undergoing upfront surgery: a systematic review","volume":"12","author":"Hagens","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154988_bib234","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.21.01831","article-title":"Immunotherapy in patients with locally advanced esophageal carcinoma: ASCO treatment of locally advanced esophageal carcinoma guideline rapid recommendation update","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib235","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.552822","article-title":"LncRNA MAGI2-AS3 overexpression sensitizes esophageal cancer cells to irradiation through down-regulation of HOXB7 via EZH2","volume":"8","author":"Cheng","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.prp.2023.154988_bib236","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.7150\/jca.55661","article-title":"TRA2A binds with LncRNA MALAT1 to promote esophageal cancer progression by regulating EZH2\/\u03b2-catenin pathway","volume":"12","author":"Zhao","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib237","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1002\/cam4.2245","article-title":"Improved characterization of the relationship between long intergenic non\u2010coding RNA Linc00152 and the occurrence and development of malignancies","volume":"8","author":"Xu","year":"2019","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib238","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12943-014-0284-y","article-title":"SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells","volume":"14","author":"Koumangoye","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib239","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106678","article-title":"Noncoding RNAs in esophageal cancer: A glimpse into implications for therapy resistance","author":"Yang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prp.2023.154988_bib240","first-page":"6543","article-title":"miR-101 suppresses tumor proliferation and migration, and induces apoptosis by targeting EZH2 in esophageal cancer cells","volume":"7","author":"Lin","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.prp.2023.154988_bib241","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/1354750X.2015.1118537","article-title":"Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients","volume":"21","author":"Liu","year":"2016","journal-title":"Biomarkers"},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib242","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12935-020-01534-y","article-title":"Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India","volume":"20","author":"Rehman","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2023.154988_bib243","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.21037\/jgo-21-776","article-title":"Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma","volume":"12","author":"Zheng","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib244","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ejso.2020.09.039","article-title":"Cholangiocarcinoma miscoding in hepatobiliary centres","volume":"47","author":"Selvadurai","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib245","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12885-019-5391-0","article-title":"Molecular pathogenesis of cholangiocarcinoma","volume":"19","author":"Labib","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib246","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.prp.2023.154988_bib247","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1155\/2010\/704759","article-title":"Cholangiocarcinoma: has there been any progress?","volume":"24","author":"Meza-Junco","year":"2010","journal-title":"Can. J. Gastroenterol."},{"key":"10.1016\/j.prp.2023.154988_bib248","article-title":"miRNA and lncRNA as biomarkers in cholangiocarcinoma (CCA)","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154988_bib249","article-title":"ARID1A variations in cholangiocarcinoma: clinical significances and molecular mechanisms","volume":"11","author":"Zhao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0747-x","article-title":"SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2\/LSD1\/DNMT1 and sponging miR-101-3p in cholangiocarcinoma","volume":"37","author":"Xu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2023.154988_bib251","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/PAS.0000000000000125","article-title":"Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma","volume":"38","author":"Sasaki","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2023.154988_bib252","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-014-0271-6","article-title":"EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3","volume":"31","author":"Tang","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.prp.2023.154988_bib253","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00268-005-7761-9","article-title":"Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma","volume":"29","author":"Nakagawa","year":"2005","journal-title":"World J. Surg."},{"key":"10.1016\/j.prp.2023.154988_bib254","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/path.2345","article-title":"Over\u2010expression of polycomb group protein EZH2 relates to decreased expression of p16INK4a in cholangiocarcinogenesis in hepatolithiasis","volume":"215","author":"Sasaki","year":"2008","journal-title":"J. Pathol.: A J. Pathol. Soc. Gt. Br. Irel."},{"issue":"1","key":"10.1016\/j.prp.2023.154988_bib255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-015-1359-x","article-title":"microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta\/Smad pathway","volume":"15","author":"Qiao","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2023.154988_bib256","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/j.gastro.2022.05.007","article-title":"NOTCH-YAP1\/TEAD-DNMT1 axis drives hepatocyte reprogramming into intrahepatic cholangiocarcinoma","volume":"163","author":"Hu","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.prp.2023.154988_bib257","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3892\/ol.2013.1559","article-title":"A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma","volume":"6","author":"Paolicchi","year":"2013","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2023.154988_bib258","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3892\/or.2013.2922","article-title":"Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells","volume":"31","author":"Nakagawa","year":"2014","journal-title":"Oncol. Rep."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823006891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823006891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T11:52:30Z","timestamp":1730893950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823006891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":258,"alternative-id":["S0344033823006891"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154988","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EZH2 as a potential therapeutic target for gastrointestinal cancers","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154988"}}